Go Pro
Leerink Partners

Leerink Partners Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Leerink Partners. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Leerink Partners' equity research team. MarketBeat is not affiliated with or endorsed by Leerink Partners.

Average Return
00.00% 12-Month ROI
Total Ratings
417 Last 12 Months
Buy Ratings
277 Last 12 Months
Sell Ratings
2 Last 12 Months
Companies Covered
234 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
$5.52
-18.3%
9/10/2026Lower Price Target$27.00OutperformView details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
$37.51
-0.6%
9/9/2026Boost Price Target$50.00 ➝ $65.00OutperformView details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026
Evommune, Inc. stock logo
EVMN
Evommune
$10.46
-3.5%
9/9/2026Lower Price Target$28.00 ➝ $22.00OutperformView details for Leerink Partners rating of Evommune (NYSE:EVMN) on 9/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.58
-1.2%
9/9/2026Initiated Coverage$24.00OutperformView details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$22.92
-1.9%
9/9/2026 Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$16.87
-2.2%
9/9/2026Initiated Coverage$23.00OutperformView details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.37
-3.5%
9/9/2026Initiated Coverage$10.00Market PerformView details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
$36.58
-2.6%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026
Viatris Inc. stock logo
VTRS
Viatris
$16.38
-0.7%
9/9/2026Initiated Coverage$20.00OutperformView details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$16.87
-2.2%
9/9/2026Initiated Coverage$23.00OutperformView details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$71.46
+1.1%
9/9/2026 Initiated Coverage$104.00OutperformView details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 9/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.58
-1.2%
9/9/2026Initiated Coverage$24.00OutperformView details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$22.92
-1.9%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
$36.58
-2.6%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.68
-1.9%
9/9/2026Boost Price Target$127.00 ➝ $161.00OutperformView details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 9/9/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$0.99
-11.6%
9/9/2026Initiated Coverage$4.00OutperformView details for Leerink Partners rating of Nautilus Biotechnology (NASDAQ:NAUT) on 9/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$25.16
-2.8%
9/9/2026Initiated Coverage$28.00Market PerformView details for Leerink Partners rating of Pacira BioSciences (NASDAQ:PCRX) on 9/9/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.37
-3.5%
9/9/2026UpgradeHoldView details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$36.34
-1.4%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 9/9/2026
Viatris Inc. stock logo
VTRS
Viatris
$16.38
-0.7%
9/9/2026Initiated Coverage$20.00OutperformView details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.06
-3.3%
9/8/2026Set Price Target$15.00View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/8/2026
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$21.51
-2.2%
9/1/2026 Initiated Coverage$36.00OutperformView details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026
Latigo Biotherapeutics, Inc. stock logo
LTGO
Latigo Biotherapeutics
$21.54
-5.5%
9/1/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$21.51
-2.2%
9/1/2026 Initiated Coverage$36.00OutperformView details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026
Latigo Biotherapeutics, Inc. stock logo
LTGO
Latigo Biotherapeutics
$21.54
-5.5%
9/1/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026
ATTO
Attovia Therapeutics
$22.53
-1.4%
8/31/2026Initiated Coverage$52.00OutperformView details for Leerink Partners rating of Attovia Therapeutics (NASDAQ:ATTO) on 8/31/2026
Scribe Therapeutics Inc. stock logo
SCTX
Scribe Therapeutics
$29.47
+0.2%
8/18/2026Initiated Coverage$37.00OutperformView details for Leerink Partners rating of Scribe Therapeutics (NASDAQ:SCTX) on 8/18/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$793.26
-1.8%
8/17/2026Boost Price Target$641.00 ➝ $824.00Market PerformView details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 8/17/2026
Freenome stock logo
FRNM
Freenome
$14.79
-6.1%
8/14/2026Initiated Coverage$18.00OutperformView details for Leerink Partners rating of Freenome (NASDAQ:FRNM) on 8/14/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$289.25
+0.4%
8/14/2026Initiated Coverage$330.00OutperformView details for Leerink Partners rating of Ligand Pharmaceuticals (NASDAQ:LGND) on 8/14/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.00
-3.1%
8/12/2026Upgrade$12.00 ➝ $13.00UnderperformMarket PerformView details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 8/12/2026
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$235.96
-1.7%
8/11/2026Set Price Target$292.00View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/11/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
$1.95
-8.5%
8/11/2026 Set Price Target$4.00View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 8/11/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.88
-3.6%
8/11/2026 Upgrade$4.00Market PerformOutperformView details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 8/11/2026
Natera, Inc. stock logo
NTRA
Natera
$326.14
-1.3%
8/7/2026 Set Price Target$330.00View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 8/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.95
-0.8%
8/7/2026Downgrade$1.00OutperformMarket PerformView details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 8/7/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$107.00
-0.4%
8/7/2026Upgrade$83.00 ➝ $110.00Market PerformOutperformView details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 8/7/2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.35
+0.3%
8/6/2026 Set Price Target$5.00View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$57.43
-1.5%
8/6/2026 Downgrade$52.00OutperformMarket PerformView details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/6/2026
Insulet Corporation stock logo
PODD
Insulet
$134.68
-2.3%
8/6/2026Downgrade$247.00 ➝ $145.00OutperformMarket PerformView details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 8/6/2026
This looks like plywood. It's not. (Ad)

AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.tc pixel

See the three companies behind this AI power breakthrough now
Replimune Group, Inc. stock logo
REPL
Replimune Group
$13.24
-8.4%
8/4/2026Upgrade$11.00 ➝ $17.00Market PerformOutperformView details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$11.17
-1.2%
8/4/2026 Lower Price Target$30.00 ➝ $23.00OutperformView details for Leerink Partners rating of Keros Therapeutics (NASDAQ:KROS) on 8/4/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.39
-0.3%
8/3/2026 Set Price Target$102.50View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026
Incyte Corporation stock logo
INCY
Incyte
$123.28
-2.2%
8/3/2026Boost Price Target$131.00 ➝ $155.00OutperformView details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.39
-0.3%
8/3/2026 DowngradeStrong-BuyHoldView details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$43.03
-4.3%
7/30/2026Set Price Target$60.00View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 7/30/2026
Humana Inc. stock logo
HUM
Humana
$400.51
+0.1%
7/30/2026 Upgrade$513.00Market PerformOutperformView details for Leerink Partners rating of Humana (NYSE:HUM) on 7/30/2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$0.14
-10.8%
7/28/2026Upgrade$1.00Market PerformOutperformView details for Leerink Partners rating of Gossamer Bio (NASDAQ:GOSS) on 7/28/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$86.70
+0.6%
7/24/2026Upgrade$87.00 ➝ $101.00Market PerformOutperformView details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 7/24/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$583.16
-0.5%
7/23/2026 Set Price Target$620.00View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 7/23/2026
Progyny, Inc. stock logo
PGNY
Progyny
$27.08
-0.1%
7/22/2026Set Price Target$38.00View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/22/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$144.81
-0.6%
7/21/2026Downgrade$146.00 ➝ $127.00OutperformMarket PerformView details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 7/21/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$6.15
-2.8%
7/20/2026Initiated Coverage$16.00OutperformView details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 7/20/2026
Elevance Health, Inc. stock logo
ELV
Elevance Health
$416.58
+5.0%
7/17/2026Boost Price Target$364.00 ➝ $395.00Market PerformView details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/17/2026
Illumina, Inc. stock logo
ILMN
Illumina
$201.27
-1.8%
7/17/2026Boost Price Target$175.00 ➝ $210.00OutperformView details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 7/17/2026
10x Genomics stock logo
TXG
10x Genomics
$66.38
-1.4%
7/17/2026Boost Price Target$23.00 ➝ $40.00Market PerformView details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 7/17/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$360.46
+2.0%
7/17/2026Lower Price Target$573.00 ➝ $454.00OutperformView details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 7/17/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$126.85
+1.1%
7/16/2026Set Price Target$110.00View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 7/16/2026
KARD
Kardigan
$18.69
-5.0%
7/13/2026Initiated Coverage$37.00OutperformView details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 7/13/2026
NGEN
NervGen Pharma
$2.16
+1.4%
7/13/2026Initiated Coverage$10.00OutperformView details for Leerink Partners rating of NervGen Pharma (NASDAQ:NGEN) on 7/13/2026
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$4.07
-2.9%
7/13/2026Initiated Coverage$9.00OutperformView details for Leerink Partners rating of Whitehawk Therapeutics (NASDAQ:WHWK) on 7/13/2026
Bruker Corporation stock logo
BRKR
Bruker
$53.56
-1.6%
7/7/2026Boost Price Target$60.00 ➝ $70.00OutperformView details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$17.18
-5.7%
7/6/2026Initiated Coverage$38.00OutperformView details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$36.32
-6.3%
7/6/2026Initiated Coverage$40.00OutperformView details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$3.27
-3.3%
7/2/2026Lower Price Target$9.00 ➝ $7.00OutperformView details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$13.18
-3.9%
7/1/2026Boost Price Target$24.00 ➝ $29.00OutperformView details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$115.95
-2.9%
6/30/2026Boost Price Target$140.00 ➝ $148.00OutperformView details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$72.08
-0.2%
6/25/2026Set Price Target$73.00View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,122.74
-0.1%
6/25/2026Boost Price Target$1,119.00 ➝ $1,232.00OutperformView details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$55.65
-0.7%
6/25/2026Boost Price Target$122.00 ➝ $129.00OutperformView details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.06
-3.3%
6/25/2026Lower Price Target$25.00 ➝ $24.00OutperformView details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$72.08
-0.2%
6/25/2026DowngradeStrong-BuyHoldView details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$28.96
-4.5%
6/24/2026Initiated Coverage$80.00OutperformView details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$43.46
-1.0%
6/24/2026Initiated Coverage$52.00OutperformView details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.56
-1.9%
6/22/2026Boost Price Target$17.00 ➝ $18.00OutperformView details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 6/22/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$37.73
-0.7%
6/22/2026Set Price Target$30.00 ➝ $52.00OutperformView details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 6/22/2026
Altimmune, Inc. stock logo
ALT
Altimmune
$3.29
-1.8%
6/22/2026Initiated Coverage$10.00OutperformView details for Leerink Partners rating of Altimmune (NASDAQ:ALT) on 6/22/2026
uniQure N.V. stock logo
QURE
uniQure
$44.47
-3.3%
6/18/2026Boost Price Target$36.00 ➝ $70.00OutperformView details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 6/18/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$82.76
+0.2%
6/17/2026Boost Price Target$61.00 ➝ $72.00Market PerformView details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/17/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$55.65
-0.7%
6/17/2026Boost Price Target$114.00 ➝ $122.00OutperformView details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/17/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$387.69
-1.4%
6/17/2026Boost Price Target$400.00 ➝ $462.00OutperformView details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 6/17/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$42.90
-1.1%
6/16/2026 Set Price Target$52.00View details for Leerink Partners rating of Edgewise Therapeutics (NASDAQ:EWTX) on 6/16/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$3.42
-1.7%
6/15/2026Boost Price Target$7.00 ➝ $12.00OutperformView details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/15/2026
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$20.07
-3.2%
6/11/2026Downgrade$31.00 ➝ $29.00OutperformMarket PerformView details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 6/11/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$23.37
-2.6%
6/8/2026Boost Price Target$55.00 ➝ $69.00OutperformView details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 6/8/2026
Stryker Corporation stock logo
SYK
Stryker
$269.98
-2.0%
6/5/2026Lower Price Target$410.00 ➝ $407.00OutperformView details for Leerink Partners rating of Stryker (NYSE:SYK) on 6/5/2026
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
$37.60
+2.6%
6/4/2026Boost Price Target$37.00 ➝ $46.00OutperformView details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 6/4/2026
Absci Corporation stock logo
ABSI
Absci
$8.24
-4.7%
6/4/2026Initiated Coverage$12.00OutperformView details for Leerink Partners rating of Absci (NASDAQ:ABSI) on 6/4/2026
Medtronic PLC stock logo
MDT
Medtronic
$91.60
-0.3%
6/4/2026Lower Price Target$117.00 ➝ $104.00OutperformView details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/4/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$10.58
-2.1%
6/3/2026Boost Price Target$20.00 ➝ $21.00OutperformView details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 6/3/2026
Bezos… DOOMED (Ad)

A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel

Watch James Altucher's free video breakdown before the September 25 deadline.
Celcuity, Inc. stock logo
CELC
Celcuity
$85.49
-5.1%
6/2/2026Set Price Target$155.00View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 6/2/2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$3.80
-1.0%
6/2/2026Downgrade$4.00OutperformMarket PerformView details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 6/2/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$3.40
-5.6%
6/2/2026Initiated Coverage$12.00OutperformView details for Leerink Partners rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 6/2/2026
Icon Plc stock logo
ICLR
Icon
$165.69
+3.9%
5/28/2026Set Price Target$145.00View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$43.03
-4.3%
5/28/2026Lower Price Target$87.00 ➝ $74.00OutperformView details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
$2.42
-5.5%
5/28/2026Upgrade$1.00 ➝ $6.00Market PerformOutperformView details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,122.74
-0.1%
5/26/2026Set Price Target$1,119.00View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026
Seaport Therapeutics, Inc. stock logo
SPTX
Seaport Therapeutics
$23.28
+7.0%
5/26/2026Initiated Coverage$35.00OutperformView details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$126.85
+1.1%
5/22/2026Set Price Target$80.00View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026
Encompass Health Corporation stock logo
EHC
Encompass Health
$120.95
-0.5%
5/22/2026Set Price Target$152.00View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026

MarketBeat's community ratings are surveys of what our community members think about Leerink Partners and other research firms in the last 90 days. Vote "Outperform" if you believe Leerink Partners's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Leerink Partners's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
0.0out of 5 (last 90 days)
0 of 5 stars
OUTPERFORM VOTES
0 Believe will outperform the market
UNDERPERFORM VOTES
0 Believe will underperform the market

Leerink Partners' equity research team has issued ratings on 228 companies across 4 sectors over the past 12 months, covered by 19 analysts. The Leerink Partners analysts below are listed by number of ratings issued in the last year.

Leerink Partners Stock Coverage by Sector

Leerink Partners concentrates its research most heavily in Healthcare (96.2%), Industrials (0.4%) and Consumer Discretionary (0.4%). The chart below shows how Leerink Partners' 234 rated companies are distributed across all 4 sectors it covers.

Leerink Partners - Frequently Asked Questions

Leerink Partners' analysts currently have buy-equivalent ratings on 180 companies. Recent upgrades to buy include Innate Pharma, Halozyme Therapeutics, Replimune Group, Humana and Gossamer Bio.

Leerink Partners' highest-rated analysts by MarketBeat's accuracy score include Andrew Berens, Faisal Khurshid and Joseph Schwartz. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 19 analysts at Leerink Partners.

Leerink Partners has the deepest coverage in Healthcare (96.2% of rated companies), Industrials (0.4% of rated companies), Finance (0.4% of rated companies) and Consumer Discretionary (0.4% of rated companies).

Leerink Partners issued 417 ratings over the last 12 months across 234 companies — an average of roughly 35 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating, set price target and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Leerink Partners analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Leerink Partners uses Outperform, Market Perform, and Underperform as their equivalents.